Article
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2020
Johnson Douglas B, Zhao Fengmin, Noel Marcus, Riely Gregory J, Mitchell Edith P, Wright John J, Chen Helen X, Gray Robert J, Li Shuli, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanly R, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith T
Abstract excerpt
PURPOSE: Substantial preclinical evidence and case reports suggest that MEK inhibition is an active approach in tumors with BRAF mutations outside the V600 locus, and in BRAF fusions. Thus, Subprotocol R of the NCI-MATCH study tested the MEK inhibitor trametinib in this population. PATIENTS AND METHODS: The NCI-MATCH study performed genomic profiling on tumor samples from patients with solid tumors and lymphomas...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.